What Vaneltix Pharma does

Vaneltix Pharma, Inc. (formerly Urigen Pharmaceuticals, Inc.) is a privately held, pre-commercial specialty pharmaceutical company headquartered in New Brunswick, New Jersey, developing treatments in urology and women's health with a focus on Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The company targets an estimated 6+ million US patients suffering from acute pelvic pain, urgency, frequency, and painful flares, an underserved population for whom existing first-line drug therapy is acknowledged as limited.

Its lead asset, Alenura®, is a proprietary combination of heparin and alkalinized lidocaine supplied as a prefilled syringe for intravesicular bladder administration. Alkalinized lidocaine is formulated to penetrate the transitional epithelial cell layer for immediate on-demand pain relief, while heparin augments the bladder's natural glycosaminoglycan (GAG) layer, reducing inflammation and providing anti-microbial properties. Phase 2 trials have shown that the combination produces greater pain relief than either component alone, and the asset is already recognized in AUA and EAU guidelines as a first-line drug therapy option. Vaneltix pursues approval under the FDA 505(b)(2) regulatory pathway for drug repurposing, with a target NDA submission in 2025. The company also holds worldwide IP covering use, composition, and manufacturing, and has a broader pipeline spanning VNX002 (regenerative biologic), VNX003 (improved oral pentosan polysulfate), VNX004 (topical pain), and VNX005 (litoxetine for incontinence, brought in from European Phase 2 for US development).

The business model is pre-commercial and centered on out-licensing and profit-sharing economics rather than direct sales at present. Revenue is contingent on FDA approval of Alenura®; investor materials cite revenue potential above $700 million for Alenura® and peak pipeline sales above $1 billion. A Joint Development Agreement with Hyloris Pharmaceuticals NV (Belgium, December 2021) provides development funding in exchange for a commercialization profit share. Upon approval, the planned go-to-market is enterprise specialty pharma sales targeting urologists first, then OB/GYNs, with products dispensed through standard pharmaceutical distribution channels as prescription-only medications administered in clinical settings. The company has disclosed only $900,000 in equity capital raised (2020 stockholder offering), operates with a simple debt-free capital structure, and employs fewer than 10 people.

Name

Vaneltix Pharma

Legal name

Vaneltix Pharma, Inc.

Website

https://vaneltix.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Urology Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Urology pharmaceuticals
• Women's health therapeutics
• Interstitial cystitis treatment
• Intravesicular drug delivery
• Bladder pain therapies

Headquarters

HQ city

New Brunswick

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Alenura® Commercialization: Vaneltix is a specialty pharmaceutical company in pre-commercial stage, focused on development of therapeutic products. Their lead clinical program Alenura® targets IC/BPS with an estimated revenue potential of over $700M and peak sales estimated at >$1B. The company is pursuing FDA 505(b)(2) regulatory pathway for accelerated approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Vaneltix Pharma is a pre-commercial specialty pharmaceutical company that develops prescription therapeutics for urology and women's health, with lead product Alenura, a heparin and alkalinized lidocaine combination supplied as a prefilled syringe for intravesicular administration to provide on-demand relief of acute pain in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The broader pipeline adds biologic, oral, and topical candidates for bladder epithelium regeneration, oral pentosan polysulfate reformulation, topical pain relief, and stress/mixed incontinence, all pursued under the FDA 505(b)(2) drug repurposing pathway.

Product overview

Vaneltix Pharma is a specialty pharmaceutical company developing a portfolio of treatments for urology and women's health, with its flagship product Alenura® (a heparin and alkalinized lidocaine combination) in late-stage development for acute pain in IC/BPS. The pipeline includes Alenura diagnostic claim, VNX002 Biologic (regenerative therapy for damaged bladder epithelium), VNX003 Oral (improved Elmiron formulation), VNX004 Topical (enhanced pain relief), and VNX005 Oral (incontinence treatment). The company leverages the FDA 505(b)(2) regulatory pathway for drug repurposing.

Differentiator

Problem solved

Functional benefit

Products and services

• Alenura® Proprietary combination product of heparin and alkalinized lidocaine supplied as a prefilled syringe for intravesicular bladder administration, providing on-demand relief of acute pain episodes associated with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).
• Alenura Diagnostic Claim Use of the Alenura heparin/alkalinized lidocaine formulation as a diagnostic tool for fast diagnosis of pelvic pain originating from the bladder.
• VNX002 Biologic Anabolic biologic therapy intended to stimulate growth of bladder epithelium, for treatment of hemorrhagic cystitis resulting from physical trauma, radiation and chemotherapy for cancer, and severe forms of interstitial cystitis and Hunner's lesions. Currently in pre-clinical stage.
• VNX003 Oral Improved oral formulation of pentosan polysulfate (Elmiron) with better absorption and bladder targeting, designed to overcome GI discomfort and reduce systemic exposure by enabling lower doses.
• VNX004 Topical Enhanced topical pain relief formulation using alkalinized lidocaine technology adapted from Alenura into novel topical dosage forms for new indications.
• VNX005 Oral Oral treatment for stress/mixed incontinence using litoxetine, a new oral drug that has completed Phase 2 clinical development and is being developed for US Phase 2b with global Phase 3 preparation.

Quantifiable outcome

• Phase 2 trials consistently demonstrate significant separation from placebo in symptoms of pain relief
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Hyloris Pharmaceuticals NVcoreStrategic or Co-development Partner · 16 December 2021Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company. Under the agreement, Hyloris provides certain funding for the development of Alenura™ product candidate in return for a profit share if and when Alenura™ is commercialized. The partnership is designed to support the development and potential commercialization of Alenura® for treatment of acute pain in Interstitial Cystitis.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Pfizer: Through legacy Pharmacia, Pfizer historically marketed Detrol (tolterodine) for overactive bladder and remains a broad incumbent in urology. As a deep-pocketed potential acquirer, Pfizer is a relevant comparable for specialty urology commercial value.
• Astellas Pharma: Major urology incumbent with Vesicare (solifenacin) and Myrbetriq (mirabegron) for overactive bladder. Astellas represents the prototypical strategic acquirer of late-stage urology assets and the standard for specialty urology commercial infrastructure.
• AbbVie (Allergan): Markets Botox (onabotulinumtoxinA), which is used off-label in refractory IC/BPS and overactive bladder. As a broad incumbent in urology and pelvic health, AbbVie represents the strategic-acquirer profile for a late-stage IC/BPS asset.
• Johnson & Johnson (Janssen): Markets Elmiron (pentosan polysulfate), the only FDA-approved oral therapy for IC/BPS pain, and VNX003 is essentially an improved version of this drug. As the incumbent in Vaneltix's primary indication, J&J defines the competitive landscape.

Direct peers

• Aclaris Therapeutics: US clinical-stage specialty pharma developing treatments in immunology and immuno-inflammatory diseases using 505(b)(2) and reformulation approaches. Comparable as a small-cap, clinical-stage specialty pharma pursuing niche indications.
• Collegium Pharmaceutical: US specialty pharma focused on pain and responsible commercialization of abuse-deterrent formulations, frequently using 505(b)(2) pathways. Comparable in size, regulatory strategy, and commercial focus on a niche pain/urology prescriber base.
• Hyloris Pharmaceuticals: Belgian specialty pharma also focused on the 505(b)(2) repurposing pathway. Hyloris is Vaneltix's joint development partner for Alenura and shares the same hybrid specialty pharma business model, making it the most directly comparable peer.
• Harrow Health: US specialty pharma focused on niche therapeutic areas using 505(b)(2) and other repurposing strategies. Comparable in size, regulatory approach, and niche-indication commercial model to Vaneltix.
• ANI Pharmaceuticals: US specialty and generic pharma that builds its portfolio through 505(b)(2) NDAs and niche specialty launches. Comparable in capital structure, repurposing focus, and approach to underserved specialty indications.

Emerging players

• Tarsus Pharmaceuticals: Emerging US specialty pharma with a focus on underserved therapeutic areas and 505(b)(2)-style development. Comparable in stage and approach to building a multi-asset specialty franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/vaneltix-pharma-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaneltix Pharma